VRTX Vertex Pharmaceuticals Incorporated
VRTX Vertex Pharmaceuticals Incorporated
Healthcare · Biotechnology
Desk view
Market read
Scan convergence 2 scans as of 2026-10-16 2 bull converging
POC $432.61 · VWAP $467.19 · +7.0% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Coverage
2 related campaigns
VRTX Price Structure
Loading timeframes…
Peers
Every watchlist VRTX belongs to, members best 30-day change first — VRTX highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@biotech
@healthcare-scan
@healthcare
@ibb
@biotech-scan
@insider-universe
Reported the quarter ending 2026-06-30: revenue $3.33B, diluted EPS $4.31, net income $1.10B (SEC filing). Across the print the stock moved +0.3% (close before → first close after).
full note →Against street estimates
How VRTX's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
Recent news
Headlines about VRTX from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 9 days ago · Oct 8
- Vertex Pharmaceuticals price target raised to $576 from $570 at RBC Capital | Markets Insider
- Vertex to Acquire Crinetics Pharmaceuticals | Vertex ...
- Vertex Pharmaceuticals Stock Price | VRTX Stock Quote, News, and History | Markets Insider
- Vertex Reports Second Quarter 2026 Financial Results – Company Announcement - FT.com
- Vertex Reports Second Quarter 2026 Financial Results
“On or before” marks an article that arrived without a publish date — the date shown is when the desk pulled it, so the article is at least that old.
VRTX research tape
160 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.